This site is intended for healthcare professionals
FDA approves a new PET agent for prostate cancer imaging
POSLUMA® (flotufolastat F18), developed by Blue Earth Diagnostics, is the prostate-specific membrane antigen with multiple indications in PET imaging for men with PSMA-positive lesions and suspected metastasis. It can also be used for men with suspected recurrence based on higher PSA levels. It demonstrated precision even at low PSA levels, with an 83% overall detection rate.
Diagnostic Imaging
Bladder removal is not needed for muscle-invasive bladder cancer
Trimodality therapy produced outcomes similar to radial cystectomy for muscle-invasive bladder cancer, as per a study. The rates of 5-year metastasis-free survival, distant failure-free survival, failure-free survival, and cancer-specific survival were also similar with both treatment approaches, supporting trimodality therapy in cases where surgery is not an option.
Urology Times
Appendicitis could be a warning sign for colon cancer!
A population-based study on more than 230,000 patients with acute appendicitis revealed that colon cancer cases were higher in the appendicitis group, particularly in the first year after appendicitis, compared to that in the control group. This association was even stronger for right-sided colon cancer. The risk was six times higher in patients aged 40 years and above.
Twitter @rocatanho
FDA grants approval to subcutaneous epocoritamab got DLBCL
Epkinly (SC epcoritamab) can be used for treating individuals with relapsed/refractory diffuse large B-cell lymphoma treated with 2 or more lines of systemic therapy. This treatment does not require a special registry like CAR T-cell therapy, making it more available to physicians and patients in community settings. Cytokine release syndrome and fever are common adverse events.
Targeted Oncology
Weight gain in early life in men linked to prostate cancer mortality
Men who gain over 12 kg body weight before 30 years of age are at 13% higher risk of developing aggressive prostate cancer and 27% higher risk of dying from prostate cancer later in life than men who maintain their teenage body weight, says decades-long research on over 25,000 Swedish men. However, more research is needed to understand this biological link.
The Guardian
How obesity affects the risk of digestive cancers?
Another cohort study revealed that BMI measures suggesting overweight and obesity in wary and middle adulthood were associated with a higher risk of developing colorectal and non-colorectal gastrointestinal cancers. Moreover, increasing or maintaining BMI measures indicating obesity or overweight were also linked to an increased risk of digestive cancers.
Twitter @JAMANetworkOpen
US: A cancer expert chosen to head the National Institutes of Health
President Biden nominated Dr Monica Bertagnolli, a cancer researcher and surgeon, to become the first female head of the NIH. Recently she became the first female to lead NIH's National Cancer Institute. She was diagnosed with breast cancer shortly after becoming the director of NCI. She is believed to bring a patient's perspective from firsthand experience with cancer.
WDSU News
FDA suspends breast cancer drug from Byondis
Biological License Application for anti-HER2 antibody-drug conjugate [vic-]trastuzumab duocarmazine (SYD985) was suspended as the agency needed additional information. This information may need more time and resources, which could extend beyond this evaluation period. However, the firm is confident that its drug provides clinical benefits to patients.
Byondis
Palliative care for cancer surgery may not improve patient outcomes
Palliative therapies given to patients with cancer before they undergo curative treatments like surgeries and bone marrow transplants do not demonstrate any benefits or harm to patients in any way, as per a study. These findings could help deal with the short supply of palliative care specialists and better use their services for patients with unmet palliative needs.
Scienmag
Combination therapy could be better than chemotherapy for CLL
Research reveals that a combination of venetoclax and other drugs like ibrutinib was more effective than chemotherapy as first-line therapy in younger and fitter patients with chronic lymphocytic leukemia. Patients treated with venetoclax also experienced fewer side effects, suggesting a new way to design safe and temporary drug combinations for CLL.
Ecancer
